Triple Therapy in COPD

被引：0
作者：
Micheletto, Claudio [1 ]
Sparacino, Alice [2 ]
机构：
[1] Univ Hosp, Resp Unit, Verona, Italy
[2] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy
来源：
CURRENT RESPIRATORY MEDICINE REVIEWS | 2019年 / 15卷 / 02期
关键词：
COPD; patients; pharmacological treatment; triple therapy; Global Initiative for Chronic Obstructive Lung Disease (GOLD); long-acting muscarinic antagonist (LAMA); OBSTRUCTIVE PULMONARY-DISEASE; IMPROVES LUNG-FUNCTION; FLUTICASONE FUROATE/VILANTEROL; PARALLEL-GROUP; DOUBLE-BLIND; SALMETEROL/FLUTICASONE PROPIONATE; PHARMACOLOGICAL CHARACTERIZATION; COMBINATION INHALER; MU-G; TIOTROPIUM;
D O I：
10.2174/1573398X15666190314151921
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Triple inhaled therapy for Chronic Obstructive Pulmonary Disease (COPD) includes an inhaled corticosteroid (ICS), a long-acting b2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) taken in combination. Triple therapy is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for patients who experience recurrent exacerbations despite treatment with either a dual bronchodilator or LABA/ICS combination. There is consistent evidence that the LABA/LAMA/ICS combination has significantly greater effects on trough FEV1, symptoms, quality of life, and exercise performance compared to comparator treatments. The role of triple therapy in reducing exacerbations in COPD patients is debatable, but recent trials have revealed some intriguing insights. Three pivotal studies, namely TRILOGY, TRINITY and TRIBUTE have been conducted to evaluate the safety and efficacy of extrafme Beclomethasone/Fonnoterol Fumarate/Glycopyrronium Bromide (BDP/FF/GB) versus different treatment options for COPD. Extrafme BDP/FF/GB has been compared to an ICS/LABA (BDP/FF) combination in the TRILOGY study, to a LAMA monotherapy (Tiotropium-TIO) and an extemporary triple combination of ICS/LABA I- LAMA (BDP/FF + TIO) in the TRINITY study, and to one inhalation of LABA/LAMA per day (Indacaterol/ Glycopyrronium - IND/GLY) in the TRIBUTE study. Another triple therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMECNI) was recently tested in two further studies that included patients with COPD. The FULFIL study compared the efficacy of the triple FF/UMECNI therapy to the ICS/LABA association budesonide/formoterol, while the IMPACT study compared the rate of moderate and severe exacerbations between singleinhaler FF/UMECNI and single-inhaler FFNI or UMECNI.
引用
收藏
页码：102 / 111
页数：10
相关论文
共 52 条
[11]   Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study [J].
D'Urzo, Anthony D. ;
Rennard, Stephen I. ;
Kerwin, Edward M. ;
Mergel, Victor ;
Leselbaum, Anne R. ;
Caracta, Cynthia F. .
RESPIRATORY RESEARCH, 2014, 15
[12]   Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD [J].
Donohue, J. F. ;
Maleki-Yazdi, M. R. ;
Kilbride, S. ;
Mehta, R. ;
Kalberg, C. ;
Church, A. .
RESPIRATORY MEDICINE, 2013, 107 (10) :1538-1546
[13]   Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials [J].
Dransfield, Mark T. ;
Bourbeau, Jean ;
Jones, Paul W. ;
Hanania, Nicola A. ;
Mahler, Donald A. ;
Vestbo, Jorgen ;
Wachtel, Andrew ;
Martinez, Fernando J. ;
Barnhart, Frank ;
Sanford, Lisa ;
Lettis, Sally ;
Crim, Courtney ;
Calverley, Peter M. A. .
LANCET RESPIRATORY MEDICINE, 2013, 1 (03) :210-223
[14]   Total and State-Specific Medical and Absenteeism Costs of COPD Among Adults Aged ≥ 18 Years in the United States for 2010 and Projections Through 2020 [J].
Ford, Earl S. ;
Murphy, Louise B. ;
Khavjou, Olga ;
Giles, Wayne H. ;
Holt, James B. ;
Croft, Janet B. .
CHEST, 2015, 147 (01) :31-45
[15]   Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN studya randomised controlled trial [J].
Frith, Peter A. ;
Thompson, Philip J. ;
Ratnavadivel, Rajeev ;
Chang, Catherina L. ;
Bremner, Peter ;
Day, Peter ;
Frenzel, Christina ;
Kurstjens, Nicol .
THORAX, 2015, 70 (06) :519-527
[16]   Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA [J].
Hahn, Beth ;
Hull, Michael ;
Blauer-Peterson, Cori ;
Buikema, Ami R. ;
Ray, Riju ;
Stanford, Richard H. .
RESPIRATORY MEDICINE, 2018, 139 :65-71
[17]   Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses [J].
Halpin, David M. G. ;
Birk, Ruby ;
Brealey, Noushin ;
Criner, Gerard J. ;
Dransfield, Mark T. ;
Hilton, Emma ;
Lomas, David A. ;
Zhu, Chang-Qing ;
Lipson, David A. .
ERJ OPEN RESEARCH, 2018, 4 (02)
[18]   Exacerbation frequency and course of COPD [J].
Halpin, David M. G. ;
Decramer, Marc ;
Celli, Bartolome ;
Kesten, Steven ;
Liu, Dacheng ;
Tashkin, Donald P. .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 :653-661
[19]   The Efficacy and Safety of the Novel Long-Acting β2 Agonist Vilanterol in Patients With COPD A Randomized Placebo-Controlled Trial [J].
Hanania, Nicola A. ;
Feldman, Gregory ;
Zachgo, Wolfgang ;
Shim, Jae-Jeong ;
Crim, Courtney ;
Sanford, Lisa ;
Lettis, Sally ;
Barnhart, Frank ;
Haumann, Brett .
CHEST, 2012, 142 (01) :119-127
[20]   Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD [J].
Hanania, Nicola A. ;
Crater, Glenn D. ;
Morris, Andrea N. ;
Emmett, Amanda H. ;
O'Dell, Dianne M. ;
Niewoehner, Dennis E. .
RESPIRATORY MEDICINE, 2012, 106 (01) :91-101
123456